Home Compare GSK.L vs IPN.PA
Stock Comparison · Cheaper and stronger

GSK vs Ipsen: Which Stock Looks Stronger in 2026?

GSK holds the cleaner structural position, with valuation as the main driver and growth adding further support. Ipsen does not offset that deficit through any equally strong structural edge elsewhere. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in valuation, but growth adds another real layer to the result. GSK plc leads by 15 points on the overall comparison score.

Trajectory Similarity
0.76
Similar
Peer-set rank: #3
within GSK plc's functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

A solid similarity means the pair shares a clearly comparable long-term financial profile, even if individual dimensions still differ.

The strongest overlap appears in capital structure and revenue stability.

Similarity drivers
capital structurerevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh
vs
IPN.PA
Ipsen S.A.
50
Peer-Score
Signal qualityMedium

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Pricing and operating quality both support the lead here.

Dimension spread: GSK.L vs IPN.PA Profitability 46 51 Stability 69 57 Valuation 80 43 Growth 71 51 GSK.L IPN.PA
Gap Ranking
#1 Valuation +37
#2 Growth +20
#3 Stability +12
#4 Profitability +5
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GSK.L and IPN.PA Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GSK.LIPN.PA Relative valuation Structural strength

GSK plc looks stronger both structurally and on relative valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
Both rank well on valuation, but GSK plc still holds a clear edge.
Growth
On growth, the same pattern holds: both rank well, but GSK plc still sits higher.
Valuation — Dominant Gap
GSK.L
80
IPN.PA
43
Gap+37in favour of GSK.L

The multiple-based pricing edge comes from a trailing P/E that is 16 turns lower.

What else supports the lead

Earnings growth is one contributing factor within the growth lead.

What this means for the comparison

Valuation is the clearest driver, and growth also supports GSK plc's broader structural position.

Explore full peer positioning in AssetNext

Break down the GSK.L vs IPN.PA comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-and-growth comparisons

Explore how GSK.L and IPN.PA each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.